|1.||Keech, Anthony C: 17 articles (09/2015 - 11/2006)|
|2.||Krysiak, Robert: 14 articles (10/2015 - 10/2004)|
|3.||Farnier, Michel: 12 articles (07/2012 - 04/2006)|
|4.||Elisaf, Moses S: 11 articles (01/2015 - 08/2003)|
|5.||Watts, Gerald F: 10 articles (09/2015 - 12/2002)|
|6.||Bordet, Régis: 10 articles (01/2015 - 07/2003)|
|7.||Staels, Bart: 10 articles (03/2014 - 12/2002)|
|8.||Jenkins, Alicia J: 9 articles (09/2015 - 02/2012)|
|9.||Ansquer, Jean-Claude: 9 articles (10/2014 - 04/2003)|
|10.||Elisaf, Moses: 9 articles (08/2014 - 01/2002)|
04/01/2006 - "The polymorphism of human IFABP gene in hyperlipidemia is related with the therapeutic efficacy of fenofibrate, and the T54T IFABP genotype may have strong negative effect on such efficacy."
01/01/1989 - "The first well-controlled studies of fenofibrate in the United States indicate that the drug is safe and effective for the treatment of type IIa and type IIb hyperlipidemia. "
03/01/2013 - "Lipid lowering studies in Triton induced hyperlipidemia rat model demonstrated higher lipid lowering ability for fenofibrate lipospheres compared to the commercial product and plain drug."
01/01/1989 - "Recent trials have investigated the usefulness of fenofibrate, alone and in combination with other lipid-lowering therapies, in the treatment of hyperlipidemia. "
09/25/2015 - "Fenofibrate is a potent agonist of PPARα and is used in the treatment of hyperlipidemia. "
08/01/2011 - "Fenofibrate monotherapy tended to improve TG and HDL-C levels to a significantly greater extent than statin monotherapy in primary dyslipidemia, whereas statin monotherapy decreased LDL-C and TC levels to a significantly greater extent than fenofibrate monotherapy. "
12/01/2002 - "Fenofibrate is effective in reducing levels of TG, TC, and LDL-C, and increasing levels of HDL-C in patients with dyslipidemias. "
11/01/2004 - "Fenofibrate at 300 mg per day is effective and safe in treating Thai patients with dyslipidemia."
10/01/1994 - "In comparison to the standard formulation, micronised fenofibrate thus provides improved efficacy in the control of dyslipidemia and the prevention of CHD."
06/01/2011 - "A trial of statin + fenofibrate in people with IR/MS and/or T2DM who also have significant dyslipidemia is needed."
05/01/1998 - "It is also effective in patients with isolated hypertriglyceridemia and, although less potent than fenofibrate at reducing TRL and increasing HDL-C, it has a greater impact on the atherogenic risk ratios such as LDL-C:HDL-C. "
06/01/2004 - "Fenofibrate is an effective, well-tolerated treatment for hypertriglyceridemia associated with HLS."
06/01/2005 - "The aim of this study was to assess the food-related efficacy of a new formulation of micronized fenofibrate coated on inert microgranules (FF-muG) for the treatment of hypertriglyceridemia in patients exhibiting the metabolic syndrome. "
08/01/2007 - "Fenofibrate therapy ameliorates fasting and postprandial lipoproteinemia, oxidative stress, and the inflammatory response in subjects with hypertriglyceridemia and the metabolic syndrome."
03/01/2006 - "In the present study, 45 subjects with hypertriglyceridemia were recruited to receive treatment with fenofibrate (200 mg/d). "
|4.||Diabetic Retinopathy (Retinopathy, Diabetic)
06/01/2015 - "The ACCORD-Eye study reported a statistically significant reduction in diabetic retinopathy progression in patients treated with fenofibrate and statin combination therapy compared to statin therapy alone. "
05/01/2012 - "Although recent clinical trials have demonstrated that fenofibrate is effective for treating diabetic retinopathy, the mechanism of this beneficial effect remains unclear. "
01/01/2013 - "Fenofibrate: a new treatment for diabetic retinopathy. "
11/01/2011 - "A consistent feature of fibrate clinical trials is the specific benefit of these agents in dyslipidaemic patients and the improvement in diabetic retinopathy with fenofibrate. "
03/01/2011 - "A consistent feature of fibrate clinical trials is the specific benefit of these agents in dyslipidaemic patients and the improvement in diabetic retinopathy with fenofibrate. "
07/01/2011 - "The aim of this study was to analyze, using homo- and heterozygous PPARα-deficient mice, the consequences of quantitative variations of PPARα gene levels and their response to the synthetic PPARα agonist fenofibrate on NASH and atherosclerosis in apoE2-KI mice. "
02/01/2008 - "As reported by the Fenofibrate Intervention and Event Lowering in Diabetes study, fenofibrate treatment has also been associated with microvascular benefits in patients with type 2 diabetes, which is consistent with preliminary evidence from the Diabetes Atherosclerosis Intervention Study. "
03/01/2005 - "Fenofibrate reduces progression to microalbuminuria over 3 years in a placebo-controlled study in type 2 diabetes: results from the Diabetes Atherosclerosis Intervention Study (DAIS)."
01/01/2002 - "Results of the initial cardiovascular morbidity/mortality outcomes study with fenofibrate (known as DAIS [Diabetes Atherosclerosis Intervention Study]) were encouraging vis-à-vis slowing of atherosclerotic progression in the coronary vasculature of type II diabetics. "
05/01/2000 - "To study the mechanism of regression of atherosclerosis (AS) by lipanthyl. "
|8.||Peroxisome Proliferator-Activated Receptors (PPAR)
|3.||Laser Therapy (Surgery, Laser)
|5.||Angioplasty (Angioplasty, Transluminal)